The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases

Figure 2

Pace of pharmacotherapy adoption in NSCLC (a) US (ASCO) and (b) EU (ESMO) guidelines. Classes of pharmacotherapies: (I) antiangiogenic + chemotherapy/+immunotherapy; (II) Checkpoint inhibitors; (III) chemotherapy; (IV) immunotherapy + chemotherapy; (V) tyrosine kinase inhibitor combination therapy; (VI) tyrosine kinase inhibitors; (VII) antibody drug conjugate. Note. Carboplatin and cisplatin were approved in Europe prior to establishment of EMA. NSCLC = non-small cell lung cancer; ASCO = American society of clinical oncology; ESMO = European society for medical oncology; US = United States; EU = European Union; EMA = European medicines agency.

(a)

(b)